A phase I/II clinical trial (NCT02798406) evaluated the antitumor efficiency of the oncolytic adenovirus DNX-2401 combined with the anti-PD-1 antibody pembrolizumab in recurrent GBM patients [240]. The gene discussed is PDCD1; the disease is glioblastoma.